MASLD and MASH: prioritising a global public health threat

Liver Disease: metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH).

Michael Guterbock
Michael Guterbock
Senior Consultant, Economist Enterprise, Policy and insights

18 Sept 2024

MASLD and MASH: prioritising a global public health threat

The country policy profiles included below for Germany, Japan, and the United States provide an overview of the current policy landscape of MASLD and MASH in each country. The profiles provide a top-level overview of the current state of MASLD and MASH care, with key policy takeaways and opportunities to enhance MASLD and MASH care in the future.

Country profiles

Germany

Japan

United States